Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Otsuka looks to maximise growth before Abilify watershed

This article was originally published in Scrip

Executive Summary

Otsuka Holdings has unveiled its first mid-term business plan since going public in a $2.4 billion IPO in Japan late last year, under which it is looking to raise net sales of pharmaceuticals (including nutrition solutions) to ¥847.0 billion ($10.47 billion) in the fiscal year to 31 March 2014, up from ¥721.4 billion last fiscal year.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC012941

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel